Literature DB >> 22528158

Influenza virus surveillance, vaccine strain selection, and manufacture.

Klaus Stöhr1, Doris Bucher, Tony Colgate, John Wood.   

Abstract

As outlined in other chapters, the influenza virus, existing laboratory diagnostic abilities, and disease epidemiology have several peculiarities that impact on the timing and processes for the annual production of influenza vaccines. The chapter provides an overview on the key biological and other factors that influence vaccine production. They are the reason for an "annual circle race" beginning with global influenza surveillance during the influenza season in a given year to the eventual supply of vaccines 12 months later in time before the next seasonal outbreak and so on. As influenza vaccines are needed for the Northern and Southern Hemisphere outbreaks in fall and spring, respectively, global surveillance and vaccine production has become a year round business. Its highlights are the WHO recommendations on vaccine strains in February and September and the eventual delivery of vaccine doses in time before the coming influenza season. In between continues vaccine strain and epidemiological surveillance, preparation of new high growth reassortments, vaccine seed strain preparation and development of standardizing reagents, vaccine bulk production, fill-finishing and vaccine release, and in some regions, clinical trials for regulatory approval.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528158     DOI: 10.1007/978-1-61779-621-0_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  32 in total

1.  Compensatory hemagglutinin mutations alter antigenic properties of influenza viruses.

Authors:  Jaclyn L Myers; Katherine S Wetzel; Susanne L Linderman; Yang Li; Colleen B Sullivan; Scott E Hensley
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

2.  Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season.

Authors:  Susanne L Linderman; Benjamin S Chambers; Seth J Zost; Kaela Parkhouse; Yang Li; Christin Herrmann; Ali H Ellebedy; Donald M Carter; Sarah F Andrews; Nai-Ying Zheng; Min Huang; Yunping Huang; Donna Strauss; Beth H Shaz; Richard L Hodinka; Gustavo Reyes-Terán; Ted M Ross; Patrick C Wilson; Rafi Ahmed; Jesse D Bloom; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

3.  Haemagglutinin mutations and glycosylation changes shaped the 2012/13 influenza A(H3N2) epidemic, Houston, Texas.

Authors:  K M Stucker; S A Schobel; R J Olsen; H L Hodges; X Lin; R A Halpin; N Fedorova; T B Stockwell; A Tovchigrechko; S R Das; D E Wentworth; J M Musser
Journal:  Euro Surveill       Date:  2015-05-07

4.  Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models.

Authors:  Huayue Ye; Siyue Jia; Yuhui Zhang; Jingxin Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

5.  Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance.

Authors:  Martina Kosikova; Lei Li; Peter Radvak; Zhiping Ye; Xiu-Feng Wan; Hang Xie
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

6.  Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.

Authors:  Esteban Cruz; Joel Cain; Ben Crossett; Veysel Kayser
Journal:  Hum Vaccin Immunother       Date:  2017-11-17       Impact factor: 3.452

7.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

8.  Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.

Authors:  Alaina J Mooney; Zhuo Li; Jon D Gabbard; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses.

Authors:  Benjamin S Chambers; Yang Li; Richard L Hodinka; Scott E Hensley
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 10.  Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.

Authors:  Scott E Hensley
Journal:  Curr Opin Virol       Date:  2014-08-11       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.